Recommended Topic Related To:

Hectorol

"Analysis of three biomarkers in the urine of kidney transplant recipients can diagnose — and even predict — transplant rejection, according to results from a clinical trial sponsored by the National Institute of Allergy and Infect"...

Hectorol

Side Effects
Interactions

SIDE EFFECTS

Dialysis

Hectorol (doxercalciferol liquid filled capsule) has been evaluated for safety in clinical studies in 165 patients with chronic kidney disease on hemodialysis. In two placebo-controlled, double-blind, multicenter studies, discontinuation of therapy due to any adverse event occurred in 2.9% of 138 patients treated with Hectorol (doxercalciferol liquid filled capsule) for four to six months (dosage titrated to achieve target iPTH levels, see CLINICAL PHARMACOLOGY/Clinical Studies) and in 3.3% of 61 patients treated with placebo for two months. Adverse events occurring in the Hectorol (doxercalciferol liquid filled capsule) group at a frequency of 2% or greater and more frequently than in the placebo group are presented in Table 3 below:

Table 3: Adverse Events Reported by ≥ 2% of Hectorol® (doxercalciferol liquid filled capsule) Treated Patients and More Frequently Than Placebo During the Double-blind Phase of Two Clinical Studies

Adverse Event Hectorol®
(n=61) %
Placebo
(n=61) %
Body as a Whole
  Abscess 3.3 0.0
  Headache 27.9 18.0
  Malaise 27.9 19.7
Cardiovascular System
  Bradycardia 6.6 4.9
Digestive System
  Anorexia 4.9 3.3
  Constipation 3.3 3.3
  Dyspepsia 4.9 1.6
  Nausea/Vomiting 21.3 19.7
Musculoskeletal System
  Arthralgia 4.9 0.0
Metabolic and Nutritional
  Edema 34.4 21.3
  Weight increase 4.9 0.0
Nervous System
  Dizziness 11.5 9.8
  Sleep disorder 3.3 0.0
Respiratory System
  Dyspnea 11.5 6.6
Skin
  Pruritus 8.2 6.6
A patient who reported the same medical term more than once was counted only once for that medical term.

Pre-dialysis

Hectorol (doxercalciferol liquid filled capsule) has been evaluated for safety in clinical studies in 55 patients (27 active and 28 placebo) with chronic kidney disease, Stages 3 or 4. In two placebo-controlled, double-blind, multicenter studies, discontinuation of therapy due to any adverse event occurred in one (3.7%) of 27 patients treated with Hectorol (doxercalciferol liquid filled capsule) for 24 weeks (dosage titrated to achieve target iPTH levels, see CLINICAL PHARMACOLOGY/Clinical Studies) and in three (10.7%) of 28 patients treated with placebo for 24 weeks. Adverse events occurring in the Hectorol (doxercalciferol liquid filled capsule) group at a frequency of 5% or greater and more frequently than in the placebo group are as follows: Body as a Whole - Infection, Chest Pain; Digestive System - Constipation, Dyspepsia; Hematologic and Lymphatic - Anemia; Metabolic and Nutritional - Dehydration; Nervous System - Depression, Hypertonia, Insomnia, Paresthesia; Respiratory System - Cough increased, Dyspnea, Rhinitis.

Potential adverse effects of Hectorol (doxercalciferol liquid filled capsule) are, in general, similar to those encountered with excessive vitamin D intake. The early and late signs and symptoms of vitamin D intoxication associated with hypercalcemia include:

Early

Weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, metallic taste, and anorexia.

Late

Polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated blood urea nitrogen (BUN), albuminuria, hypercholesterolemia, elevated serum aspartate transaminase (AST) and alanine transaminase (ALT), ectopic calcification, hypertension, cardiac arrhythmias, sensory disturbances, dehydration, apathy, arrested growth, urinary tract infections, and, rarely, overt psychosis.

Read the Hectorol (doxercalciferol liquid filled capsule) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Specific drug interaction studies have not been conducted. Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; therefore, it may impair intestinal absorption of doxercalciferol. Magnesium-containing antacids and Hectorol (doxercalciferol liquid filled capsule) should not be used concomitantly because such use may lead to the development of hypermagnesemia (see WARNINGS). The use of mineral oil or other substances that may affect absorption of fat may influence the absorption and availability of Hectorol (doxercalciferol liquid filled capsule) . Although not examined specifically, enzyme inducers (such as glutethimide and phenobarbital) may affect the 25-hydroxylation of Hectorol (doxercalciferol liquid filled capsule) and may necessitate dosage adjustments. Cytochrome P450 inhibitors (such as ketoconazole and erythromycin) may inhibit the 25-hydroxylation of Hectorol (doxercalciferol liquid filled capsule) . Hence, formation of the active Hectorol (doxercalciferol liquid filled capsule) moiety may be hindered.

Read the Hectorol Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 4/12/2011
This monograph has been modified to include the generic and brand name in many instances.

Side Effects
Interactions
A A A

Hectorol - User Reviews

Hectorol User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Hectorol sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.